| 52.51 -0.09 (-0.17%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 61.54 | 1-year : | 71.88 |
| Resists | First : | 52.68 | Second : | 61.54 |
| Pivot price | 38.25  |
|||
| Supports | First : | 38.34 | Second : | 29.46 |
| MAs | MA(5) : | 49.84 |
MA(20) : | 37.2 |
| MA(100) : | 42.87 |
MA(250) : | 60.39  |
|
| MACD | MACD : | 3.2 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 99.5 |
D(3) : | 99 |
| RSI | RSI(14): 77.8 |
|||
| 52-week | High : | 90.31 | Low : | 29.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SLNO ] has closed below upper band by 9.8%. Bollinger Bands are 257.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 52.62 - 52.89 | 52.89 - 53.06 |
| Low: | 51.76 - 52.12 | 52.12 - 52.35 |
| Close: | 52 - 52.54 | 52.54 - 52.88 |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Wed, 08 Apr 2026
INVESTOR ALERT: Soleno Therapeutics Inc. (SLNO) Investors - GlobeNewswire
Wed, 08 Apr 2026
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Wed, 08 Apr 2026
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 129 (%) |
| Shares Short | 9,330 (K) |
| Shares Short P.Month | 9,700 (K) |
| EPS | 0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.6 |
| Profit Margin | 10.9 % |
| Operating Margin | 44 % |
| Return on Assets (ttm) | 2 % |
| Return on Equity (ttm) | 6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 3.63 |
| Sales Per Share | 3.68 |
| EBITDA (p.s.) | 0.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 47 (M) |
| Levered Free Cash Flow | 48 (M) |
| PE Ratio | 134.64 |
| PEG Ratio | 0 |
| Price to Book value | 6.09 |
| Price to Sales | 14.23 |
| Price to Cash Flow | 57.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|